XML 29 R14.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 6 - Restructuring and Other Exit Costs
12 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Restructuring and Related Activities Disclosure [Text Block]
 

6.

Restructuring and Other Exit Costs

 

On an ongoing basis, the Company reviews the global economy, the healthcare industry, and the markets in which it competes to identify operational efficiencies, enhance commercial capabilities and align its cost base and infrastructure with customer needs and its strategic plans. In order to realize these opportunities, the Company undertakes activities from time to time to transform its business. A portion of these transformation activities are considered restructuring costs under ASC 420 Exit or Disposal Cost Obligations and are discussed below.

 

During 2019, the Company initiated a restructuring program to improve operational efficiency and reduce costs which entailed consolidating and downsizing several sites and headcount reductions in Europe and North America. The Company incurred approximately $4.7 million of costs under this program which was completed in 2021.

 

The following table summarizes the activity for accrued restructuring liability for the years ended December 31, 2021 and 2020:

 

(in thousands)

 

Severance

  

Other

  

Total

 

Balance at December 31, 2019

 $364  $4  $368 

Restructuring and other exit costs

  1,625   408   2,033 

Non-cash charges

  -   (168)  (168)

Cash payments

  (1,719)  (226)  (1,945)

Balance at December 31, 2020

 $270  $18  $288 

Restructuring and other exit costs

  1,174   101   1,275 

Non-cash charges

  -   (46)  (46)

Cash payments

  (1,444)  (73)  (1,517)

Balance at December 31, 2021

 $-  $-  $- 

 

Substantially all of these restructuring costs have been included as a component of general and administrative expenses.